Abs 0359 TULIP-1&2 data showed nearly 10% of anifrolumab-treated pts achieved remission, suggesting that DORIS response is attainable. #ACR22 @RheumNow https://t.co/laPwd0KpSa https://t.co/6LZ1WLrc97
Links:
Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1…
http://ow.ly/v8kR50LvAel
13-11-2022
